Systemic targeted therapy for HER2-positive early female breast cancer: A systematic review of the evidence for the 2014 cancer care Ontario systemic therapy guideline

Current Oncology

Volumn 22, Issue , 2015, Pages S114-S122

  Mates, Mihaela ^a   Fletcher, G G ^b   Freedman, O C ^c   Eisen, A ^d   Gandhi, S ^d   Trudeau, M E ^d   Dent, S F ^e  

^a KINGSTON GENERAL HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Durham Regional Cancer Centre   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Early breast cancer; HER2; Lapatinib; Pertuzumab; Targeted therapy; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; HUMAN; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 84940379129     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2322     Document Type: Article

References (69)

1. Berry DA, Cronin KA, Plevritis SK, et al. on behalf of the Cancer Intervention and Surveillance Modeling Network (cisnet) collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92.
2. Eisen A, Srikanthan A, Yeung L, Iyer R, Trudeau M. Provincial variation in utilization of adjuvant chemotherapy regimens in early stage breast cancer: data from the Cancer Care Ontario New Drug Funding Program (ndfp) [abstract P3-12-1]. Cancer Res 2013;73:.
3. Eisen A, Fletcher GG, Gandhi S, et al. Optimal Systemic Therapy for Early Female Breast Cancer. Evidence-based series 1-21. Toronto, ON: Cancer Care Ontario; 2014. [Available online at: https://www.cancercare.on.ca/toolbox/quality guidelines/diseasesite/breast-ebs; cited August 19, 2014]
4. Singletary SE, Allred C, Ashley P, et al. Part vii. Breast. In: Greene FL, Page DL, Fleming ID, et al., eds. American Joint Committee on Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002: 221-40.
5. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
6. Shea BJ, Grimshaw JM, Wells GA, et al. Development of amstar: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10. [Available online at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC1810543/pdf/1471-2288-7-10.pdf; cited December 7, 2013]
7. National Institute for Health and Clinical Excellence (nice). Early and Locally Advanced Breast Cancer: Diagnosis and Treatment. Clinical guideline 80. Cardiff, Wales: nice; 2009.
8. Members of the Breast Cancer Disease Site Group. The Role of Trastuzumab in Adjuvant and Neoadjuvant Therapy in Women with HER2/neu-Overexpressing Breast Cancer. Evidence-based series 1-24. Ver. 2. Toronto, ON: Cancer Care Ontario; 2011. [Available online at: https://www.cancercare.on.ca/common/ pages/UserFile.aspx?fileId=13890; cited May 24, 2012]
9. Members of the Breast Cancer Disease Site Group. The Role of HER2/neu in Systemic and Radiation Therapy for Women with Breast Cancer. Evidence-based series 1-17. Toronto, ON: Cancer Care Ontario; 2011. [Available online at: https://www. cancercare.on.ca/common/pages/UserFile.aspx?fileId=13878; cited October 6, 2012]
10. Australia, National Breast Cancer Centre. Recommendations for Use of Trastuzumab (Herceptin) for the Treatment of HER2-Positive Breast Cancer. Camperdown, Australia: Cancer Australia; 2007. [Available online at: http://guidelines. canceraustralia.gov.au/guidelines/guideline_5.pdf; cited May 24, 2012]
11. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012;4:CD006243. [Available online at: http://www.mrw. interscience.wiley.com/cochrane/clsysrev/articles/CD006243/ frame.html; cited May 22, 2012]
12. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the finher trial. J Clin Oncol 2009;27:5685-92.
13. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33.
14. Slamon D, Eiermann W, Robert N, et al. on behalf of the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
15. Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011;29:4491-7.
16. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS ONE 2011;6:e21030.
17. Valachis A, Mauri D, Polyzos NP, Chlouverakis G, Mavroudis D, Georgoulias V. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 2011;20:485-90.
18. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs 2011;22:128-35.
19. Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010;116:2856-67.
20. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H. Adjuvant/neoadjuvant trastuzumab therapy in women with her-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008;34:539-57.
21. Dent S, Oyan B, Honig A, Mano M, Howell S. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev 2013;39:622-31.
22. Chen T, Xu T, Li Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 2011;37:312-20.
23. Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 2010;21:2153-60.
24. Gianni L, Dafni U, Gelber RD, et al. on behalf of the Herceptin Adjuvant (hera) trial study team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12:236-44.
25. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 Years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (hera): an open-label, randomised controlled trial. Lancet 2013;382:1021-8.
26. Baselga J, Bradbury I, Eidtmann H, et al. on behalf of the neoaltto study team. Lapatinib with trastuzumab for HER2-positive early breast cancer (neoaltto): a randomised, openlabel, multicentre, phase 3 trial. Lancet 2012;379:633-40. [Erratum in: Lancet 2012;379:616]
27. Azim HA Jr, Agbor-Tarh D, Bradbury I, et al. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the neoaltto trial. J Clin Oncol 2013;31:4504-11. [Erratum in: J Clin Oncol 2014;32:365]
28. Buzdar AU, Suman VJ, Meric-Bernstam F, et al. on behalf of the American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (fec-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by fec-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14:1317-25.
29. Buzdar A, Suman V, Meric-Bernstam F, et al. Preliminary safety data of a randomized phase iii trial comparing a preoperative regimen of fec-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by fec-75 plus trastuzumab in patients with HER2-positive operable breast cancer (acosog Z1041) [abstract 594]. J Clin Oncol 2010;28:. [Available online at: http://meeting. ascopubs.org/cgi/content/abstract/28/15_suppl/594; cited December 21, 2014]
30. Untch M, Loibl S, Bischoff J, et al. on behalf of the German Breast Group (gbg) and the Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (ago-b) study group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, gbg 44): a randomised phase 3 trial. Lancet Oncol 2012;13:135-44.
31. von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011;22:301-6.
32. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
33. Masuda N, Toi M, Ueno T, et al. A multicenter, randomized phase ii study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (jbcrg-10 study) [abstract TPS105]. J Clin Oncol 2010;28:. [Available online at: http:// meetinglibrary.asco.org/content/50280-74; cited December 21, 2014]
34. Masuda N, Sato N, Higaki K, et al. A prospective multicenter randomized phase ii neo-adjuvant study of 5-fluorouracil, epirubicin and cyclophosphamide (fec) followed by docetaxel, cyclophosphamide and trastuzumab (tch) versus tch followed by fec versus tch alone, in patients (pts) with operable HER2 positive breast cancer: jbcrg-10 study [abstract P1-14-08]. Cancer Res 2012;72:15s.
35. Hofmann D, Nitz U, Gluz O, et al. wsg adapt-Adjuvant Dynamic Marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase ii/iii trial. Trials 2013;14:261. [Available online at: http:// www.trialsjournal.com/content/14/1/261; cited July 16, 2014]
36. Joensuu H, Sperinde J, Leinonen M, et al. Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol 2011;22:2007-13.
37. Pauporte I, Faure C, Pivot X. Boosting French clinical research in breast cancer: the example of the phare trial [French]. Oncologie 2009;11:348-52.
38. Pivot X, Romieu G, Bonnefoi H, et al. phare trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer [abstract LBA5_PR]. Ann Oncol 2012;23(suppl 9):ixe2. [Available online at: http://annonc.oxfordjournals.org/ content/23/suppl_9/ixe1.full.pdf+html?sid=7d4228f6-c180-4859-807c-25ac57d5b1fb; cited October 11, 2012]
39. Pivot X, Romieu G, Debled M, et al. on behalf of the phare trial investigators. 6 Months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (phare): a randomised phase 3 trial. Lancet Oncol 2013;14:741-8.
40. Sledge GW, O'Neill A, Thor A, et al. Adjuvant trastuzumab: long-term results of E2198 [abstract 2075]. Breast Cancer Res Treat 2006;100(suppl 1):S106.
41. Earl H, Cameron D, Miles D, et al. persephone is a randomised phase iii controlled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2 positive early breast cancer [abstract P033]. Eur J Surg Oncol 2014;40:619.
42. Smith I, Procter M, Gelber RD, et al. on behalf of the hera study team. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
43. Untch M, Gelber RD, Jackisch C, et al. on behalf of the hera study team. Estimating the magnitude of trastuzumab effects within patient subgroups in the hera trial. Ann Oncol 2008;19:1090-6.
44. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (big 1-01). J Clin Oncol 2014;32:2159-65.
45. Pestalozzi BC, Holmes E, de Azambuja E, et al. cns relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the hera trial (big 1-01). Lancet Oncol 2013;14:244-8.
46. Goss PE, Smith IE, O'Shaughnessy J, et al. on behalf of the teach investigators. Adjuvant lapatinib for women with earlystage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14:88-96. [Erratum in: Lancet Oncol 2013;14:e47]
47. Guerra YC, Chan A, Finkelstein DM, et al. Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2-ve bc): analysis of patients in the teach trial [abstract 628]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary. asco.org/content/115932-132; cited December 21, 2014]
48. Smith IE, Finkelstein DM, O'Shaughnessy J, et al. Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ bc): analysis of the hormone receptor-negative subgroup of the intent-to-treat (itt) population of the teach trial [abstract 596]. J Clin Oncol 2012;30:. [Available online at: http://meetinglibrary.asco.org/content/100845-114; cited December 21, 2014]
49. Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase iii altto trial (big 2-06; ncctg [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (l), trastuzumab alone (t), their sequence (t→l), or their combination (t+l) in the adjuvant treatment of HER2-positive early breast cancer (ebc) [abstract LBA4]. J Clin Oncol 2014;32:. [Available online at: http://meetinglibrary. asco.org/content/128258-144; cited December 21, 2014]
50. Dueck AC, Hillman DW, Kottschade LA, et al. Quality of life (qol) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the altto study (big 2-06, Alliance N063D) [abstract 647]. J Clin Oncol 2014;32:. [Available online at: http://meetinglibrary.asco.org/ content/134049-144; cited December 21, 2014]
51. Perez EA, Romond EH, Suman VJ, et al. Four-year followup of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from ncctg N9831 and nsabp B-31. J Clin Oncol 2011;29:3366-73.
52. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-8.
53. Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the asco/cap HER2-positivity criteria. J Natl Cancer Inst 2012;104:159-62.
54. Perez EA, Jenkins RB, Dueck AC, et al. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial. J Clin Oncol 2011;29:651-9.
55. Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010;28:4307-15.
56. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
57. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in nsabp B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (acp) with acp plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:3792-9.
58. Slamon D, Eiermann W, Robert N, et al. on behalf of the bcirg 006 investigators. Phase iii trial comparing ac-t with ac-th and with tch in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [slide presentation]. Presented at the 2006 San Antonio Breast Cancer Symposium; San Antonio, TX, U.S.A.; December 14-17, 2006. [Available online at: http://www.cirg.org/html/images/ BCIRG006+2nd+Interim+Analysis.pdf; cited October 27, 2011]
59. Au HJ, Eiermann W, Robert NJ, et al. on behalf of the Translational Research in Oncology bcirg 006 trial investigators. Health-related quality of life with adjuvant docetaxel-and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the bcirg 006 study. Oncologist 2013;18:812-18.
60. Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the fnclcc-PACS 04 trial. J Clin Oncol 2009;27:6129-34.
61. Sawaki M, Tokudome N, Mizuno T, et al. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [respect (n-sas BC07)]. Jpn J Clin Oncol 2011;41:709-12.
62. Fehrenbacher L, Jeong JH, Rastogi P, et al. nsabp B-47: a randomized phase iii trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer [abstract TPS1139]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary.asco.org/ content/113241-132; cited December 21, 2014]
63. Goss PE, Barrios CH, Chan A, et al. A phase iii trial of adjuvant neratinib (ner) after trastuzumab (tras) in women with early-stage HER2+ breast cancer (bc) [abstract TPS137]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary. asco.org/content/84067-102; cited December 21, 2014]
64. von Minckwitz G, Baselga J, Bradbury I, et al. Adjuvant pertuzumab and Herceptin in initial therapy of breast cancer: aphinity (big 4-11/BO25126/TOC4939g) [abstract OT1-02-4]. Cancer Res 2011;71(suppl):. [Available online at: http:// cancerres.aacrjournals.org/content/71/24_Supplement/OT1-02-04.abstract; cited January 6, 2015]
65. Breast International Group (big). The aphinity trial has reached its recruitment target ahead of schedule! [online press release]. Brussels, Belgium: big; 2014. [Available online at: http://www. bigagainstbreastcancer.org/news/aphinity-trial-has-reachedits-recruitment-target-ahead-schedule; cited July 16, 2014]
66. Goldhirsch A, Piccart M, Procter M, et al. hera trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up [abstract LBA6_PR]. Ann Oncol 2012;23:ixe2. [Available online at: http://annonc.oxfordjournals.org/content/23/suppl_9/ ixe1.full.pdf+html?sid=e1381f2a-b04f-444b-9ec4-71ec98521b77; cited January 1, 2015]
67. Petrelli F, Barni S. Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate. Med Oncol 2011;28:401-8.
68. European Society for Medical Oncology (esmo). phare trial results comparing 6 to 12 months of adjuvant trastuzumab in early breast cancer [online news article]. Viganello-Lugano, Switzerland: esmo; October 1, 2012. [Available online at: http://www.esmo.org/Conferences/Past-Conferences/ESMO-2012-Congress/News-Press-Releases/Congress-News/ PHARE-trial-results-comparing-6-to-12-months-of-adjuvanttrastuzumab-in-early-breast-cancer; cited October 11, 2012]
69. De Laurentiis M, Criscitiello C, Giordano A, et al. HER2 status and efficay [sic] of taxane-based adjuvant therapy of early breast cancer (ebc): a metanalysis of randomized trials involving 7,831 patients [abstract 707]. Cancer Res 2009;69(suppl):.